Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

BACKGROUND: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-β peptide (Aβ(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephaliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Vellas, Bruno, Black, R, Thal, Leon J, Fox, Nick C, Daniels, M, McLennan, G, Tompkins, C, Leibman, C, Pomfret, M, Grundman, Michael
Formato: Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd. 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825665/
https://www.ncbi.nlm.nih.gov/pubmed/19355849
http://dx.doi.org/10.2174/156720509787602852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825665/
https://www.ncbi.nlm.nih.gov/pubmed/19355849
http://dx.doi.org/10.2174/156720509787602852

Ejemplares similares